Quest Laboratories

Quest Laboratories P/B

The P/B (Price-to-Book Ratio) of Quest Laboratories (QUESTLAB.NS) as of Nov 6, 2026 is 2.58. In the previous year, P/B (Price-to-Book Ratio) was 7.36 — a change of -64.99% (lower).

P/B

2.58

YoY

-64.99%

Last updated:

P/B (Price-to-Book Ratio) of Quest Laboratories is 2025 2.58 . P/B (Price-to-Book Ratio) of Quest Laboratories was 2024 7.36 . It decreases by -64.99% lower compared to the previous year.

The Quest Laboratories P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2023
14.03 INR
Jan 1, 2024
7.36 INR
Jan 1, 2025
2.58 INR
The Quest Laboratories P/B history
YEARP/BYoY
2.58-64.99%
7.36-47.55%
14.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Laboratories Stock analysis

What does Quest Laboratories do? Quest Laboratories Ltd generates revenue through the manufacturing and sale of pharmaceutical formulations, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, and antidepressants. The company produces ethical drugs, generic drugs, and over-the-counter (OTC) products available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. Key products include Cetirizine Hydrochloride Tablet IP 10 mg, Zinc Sulphate Dispersible Tablet IP, Diclofenac Sodium Tablet BP, Ferrous Sulphate & Folic Acid Syrup, Albendazole Suspension IP, and Silver Sulphadiazine Cream IP, which are sold to healthcare providers and consumers through distribution networks. The company targets multiple market segments including hospitals, clinics, pharmacies, and direct consumer channels for its diverse product portfolio. Ethical drugs and generics cater to prescription-based healthcare needs, while OTC products serve self-medication demands. Products like Zinc Oral Solution USP and Alpha Amilase & Pepsine are positioned for specific therapeutic categories, ensuring broad market coverage across India's pharmaceutical landscape. Quest Laboratories Ltd focuses on producing high-quality formulations with standardized dosages and regulatory compliance, leveraging its manufacturing capabilities to serve both institutional and retail markets. The firm's product range spans critical therapeutic areas, enabling it to capture demand from various healthcare stakeholders without relying on external partnerships or third-party brands. Quest Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Laboratories stock

P/B (Price-to-Book Ratio) of Quest Laboratories is 2.58 in 2025.

P/B (Price-to-Book Ratio) of Quest Laboratories changed from 7.36 to 2.58, representing a -64.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Quest Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Quest Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quest Laboratories

All Key Metrics — Quest Laboratories